| Document |
Document Title |
|
WO/2019/231024A1 |
The present application relates to a physically pretreated biomass composition that enables chemical treatment in a biomass composition comprising a high concentration of biomass substrate, and a method for producing same. The physically...
|
|
WO/2019/226952A1 |
An oligo- or polynucleotide analogue having one or more structures of the general formula: where B is a pyrimidine or purine nucleic acid base, or an analogue thereof, is used for treating obesity-related metabolic diseases.
|
|
WO/2019/226431A1 |
A method for producing and purifying human milk oligosaccharides (HMOs) is provided. The method includes fermentation of a genetically modified microbial organism, preferably a genetically modified yeast strain, and downstream processing...
|
|
WO/2019/219895A1 |
The present invention relates to crystalline (thio)nicotinamide ribofuranoside salts, methods of making such crystalline salts, a pharmaceutical composition comprising same, and use of said crystalline salts as nutritional (dietary) supp...
|
|
WO/2019/222269A1 |
Provided are biaryl amides and coumarin-based compounds with modified sugar groups for treatment of diseases associated with heat shock protein pathway. The compounds having the following formulas, wherein variables are as defined herein...
|
|
WO/2019/222601A1 |
Methods of preparing concentrated solutions of crystalline steviol glycoside compositions having relatively high rebaudioside M content are provided herein. The concentrated solutions are stable and can be used to prepared beverage syrup...
|
|
WO/2019/215073A1 |
Provided is a method for the purification of lacto-N-neotetraose from other carbohydrates, characterized in that the method comprises the steps of subjecting an aqueous solution containing lacto-N-neotetraose to two membrane filtration s...
|
|
WO/2019/212063A1 |
Provided are: an optically active segment for stereocontrolled oligonucleotide synthesis represented by formula (I); a production method for the same; and a stereocontrolled oligonucleotide synthesis method using the same. (In the formul...
|
|
WO/2019/201268A1 |
Disclosed are a drug used for preventing and/or treating pain and/or fever, a combination product, and a use thereof; the active ingredient of said drug comprises one of carrimycin, isovaleryl spiramycin III, isovaleryl spiramycin II, an...
|
|
WO/2019/195084A1 |
Methods of extracting Nerium oleander plant species with a plant juice or plant oil are disclosed. Pharmaceutical and cosmetic compositions comprising the resulting Nerium oleander extracts and methods of using them are also disclosed.
|
|
WO/2019/193556A1 |
The invention relates to a method for extracting oligofucanes from brown algae, to the compositions resulting from said extraction, and to the applications thereof. Said method comprises the following successive steps: (a) depolymerisati...
|
|
WO/2019/189422A1 |
A method for separating steviol glycoside(s), said method involving separation step 55 for performing continuous liquid chromatography wherein a liquid to be separated, which contains multiple kinds of steviol glycosides, is passed throu...
|
|
WO/2019/178980A1 |
A method for preparing gynostemma pentaphylla makino saponin LVI, XLVI, L, LI, Damulin A or Damulin B. In said method, Gynostemma cardiospermum Cogn.ex Oliv is used as a raw material to prepare a high content of target product by means o...
|
|
WO/2019/179325A1 |
The present invention relates to the field of carbohydrate chemistry, and discloses a preparation method for a surface capsular polysaccharide structural derivative of Gram-positive bacteria. In the present invention, glucose is used as ...
|
|
WO/2019/175126A1 |
The invention comprises LNA-dicarboxylic acid derivatives of the formula I or salts thereof, wherein R1 is a nucleobase or a modified nucleobase R2 is a hydroxy protecting group and n is an integer from 1 to 5. The LNA-dicarboxylic acid ...
|
|
WO/2019/177634A1 |
Methods of preparing highly purified steviol glycosides, particularly steviolmonoside, steviolmonoside A, steviolbioside, steviolbioside A, steviolbioside B, rubusoside, stevioside, stevioside A (rebaudioside KA), stevioside B, steviosid...
|
|
WO/2019/178116A1 |
The present disclosure relates to the production of steviol glycosides rebaudioside J and rebaudioside N through the use of rebaudioside A as a substrate and a biosynthetic pathway involving various 1,2 RhaT-rhamnosyltransferases.
|
|
WO/2019/169837A1 |
The invention relates to an albumin conjunction-type maleimide functionalized gemcitabine prodrug as well as application thereof in transferring an antitumor prodrug. The albumin conjunction-type maleimide functionalized gemcitabine prod...
|
|
WO/2019/169988A1 |
The present invention relates to the field of pharmaceutical chemistry, and in particular, to the crystal forms of Ertugliflozin and preparation methods therefor. Said crystal form is crystal form I, crystal form II or crystal form III, ...
|
|
WO/2019/157561A1 |
Disclosed herein are methods and apparatuses for producing levoglucosenone and a substituted furan from lignocellulosic biomass. In one form, the method includes: converting lignocellulosic biomass, in contact with an acid within a multi...
|
|
WO/2019/160922A1 |
This specification relates to a process for preparing a dried fucosyllactose (FL) from an FL solution by spray drying. This specification also relates to an FL in powder form having high bulk density, such as is obtained by the process d...
|
|
WO/2019/154195A1 |
The present invention relates to a novel therapeutic drug for a neurodegenerative disease and an application thereof. Provided is a novel compound of formula (I). The compound can effectively facilitate the proliferation of neural stem c...
|
|
WO/2019/156907A1 |
Disclosed are co-crystal forms of N-(2-(5-(((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6 dimethyltetra-hydro-2H-pyran-2-yl)oxy)-3'-fluoro-[1,1'-biphe
nyl]-2-yl)ethyl)-acetamide and L proline or D- proline, their pharmaceutical compositions,...
|
|
WO/2019/156483A1 |
The present invention relates to a method for producing a functional crystalline sweetener and, more specifically, to a method for producing a crystalline sweetener, the method being capable of improving the crystallization yield and inc...
|
|
WO/2019/149835A1 |
A process for the conversion of a solid material containing hemicellulose, cellulose and lignin, which process comprises the following steps: (i) hydrolyzing, at a temperature equal to or less than 40°C, preferably equal to or less than...
|
|
WO/2019/149833A1 |
A process for the conversion of a solid material containing hemicellulose, cellulose and lignin, which process comprises the following steps: (i) hydrolyzing, at a temperature equal to or less than 40°C, preferably equal to or less than...
|
|
WO/2019/149834A1 |
A process for the conversion of a solid material containing hemicellulose, cellulose and lignin, which process comprises the following steps: (i) hydrolyzing, at a temperature equal to or less than 40°C, preferably equal to or less than...
|
|
WO/2019/152459A1 |
Methods for stereoselective synthesis and manufacturing of 2'-deoxynucleosides, such as 2'-ribonucleosides, are disclosed. In some embodiments, the 2'-deoxynucleoside is a β-anomer of 2'-deoxynucleoside having a 3' a hydroxyl, 4' β hyd...
|
|
WO/2019/147617A1 |
Novel diterpene glycosides isolated from Stevia extract as well as diterpene glycosides that are synthetically prepared are provided herein. Compositions and consumables comprising the novel diterpene glycosides are also provided herein....
|
|
WO/2019/144589A1 |
A method for preparing high-content trehalose. The method sequentially comprises the following steps: (1) preparing starch milk; (2) liquefying; (3) performing double enzymolysis; (4) filtering to remove protein; (5) decolorizing; (6) de...
|
|
WO/2019/145543A1 |
The invention comprises a process for the preparation of GalNAc oligonucleotide conjugates which comprises the coupling of a GalNAc cluster compound of the formula or corresponding salts, enantiomers and/ or a stereoisomer thereof, with ...
|
|
WO/2019/144588A1 |
Disclosed in the present invention is a preparation method of large-grained trehalose, the method comprises the following steps: (1) preparing starch milk, (2) liquefaction, (3) double enzymolysis, (4) removing protein by filtration, (5)...
|
|
WO/2019/140147A1 |
Methods for identifying or monitoring or treating HIV persistence or the development of an HIV-comorbidity in an HIV+ subject involve certain selected glycan dysregulations. In certain embodiments, hyposialylation in the total IgG glycom...
|
|
WO/2019/136399A1 |
A synthetic dystroglycan oligosaccharide comprising Formula (I) wherein a repeating disaccharide motif consists of Glucuronic Acid (ClcA) and Xylose (Xyl) having a defined glycosyl connection GlcA-β-(1→3)-Xyl-α-(1→3)-GlcA; wherein ...
|
|
WO/2019/128410A1 |
The present invention relates to the preparation of various xylan esterification products, and an application thereof in a drug for preventing, alleviating and/or treating inflammatory diseases. The application of a xylan esterification ...
|
|
WO/2019/127004A1 |
The present invention falls within the field of biomedical technology, and in particular relates to modified oligonucleotides and a compound that can be used for synthesizing same, and a method for modifying oligonucleotides. The present...
|
|
WO/2019/119134A1 |
An immunogenic glycan compound has a poly-β-1,4-ManNAc repeating-unit structure variably modified with 6-linked phosphoethanolamine and 6-linked phosphoglycerol.
|
|
WO/2019/120299A1 |
Provided are a liver specific delivery (LSD)-based anticancer prodrug nucleoside cyclic phosphate compound and an application thereof, and in particular, a compound represented by formula (I) as well as isomers, pharmaceutically acceptab...
|
|
WO/2019/119628A1 |
Disclosed in the present invention is a method for preparing tulathromycin.
|
|
WO/2019/122084A1 |
It relates to a process for the preparation of nicotinamide riboside chloride of formula (I) wherein R1-R4 are as defined herein, comprising the following steps: a) reacting a riboside precursor wherein the hydroxyl groups at positions 1...
|
|
WO/2019/118476A1 |
The presently disclosed subject matter relates to processes for isolating xylose from an aqueous solution. A representative process can comprise providing an aqueous solution comprising xylose; combining a boron compound with the aqueous...
|
|
WO/2019/114406A1 |
An absorbable iron-based implantable device, comprising an iron-based substrate and a hydrophobically-modified high polysaccharide attached to the iron-based substrate. The solubility of the modified high polysaccharide in an organic sol...
|
|
WO/2019/110804A1 |
Disclosed is a method for the manufacture of a spray-dried powder consisting essentially of LNT and/or LNn T, the spray-dried powder, its use for the manufacture of nutritional compositions, and nutritional compositions containing the sp...
|
|
WO/2019/110806A1 |
Disclosed is a method for the manufacture of a spray-dried powder consisting essentially of at least one lacto-N-fucopentaose, the spray-dried powder, its use for the manufacture of nutritional compositions, and nutritional compositions ...
|
|
WO/2019/110803A1 |
Disclosed is a method for the manufacture of a spray-dried powder consisting essentially of 3'-SL and/or 6'-SL, the spray-dried powder, its use for the manufacture of nutritional compositions, and nutritional compositions containing the ...
|
|
WO/2019/109300A1 |
Improved enrichment methods for preparing tannic acid compositions that have superior potency in inhibiting D-amino acid oxidase, and superior purity and safety profiles. The tannic acid compositions (e.g., pharmaceutical compositions, n...
|
|
WO/2019/110801A1 |
Disclosed is a method for the manufacture of a spray-dried powder consisting essentially of 3-fucosyllactose, the spray-dried powder, its use for the manufacture of nutritional compositions, and nutritional compositions containing the sp...
|
|
WO/2019/109833A1 |
The present utility model provides a device for continuously producing sugar by hydrolyzation using a lignocellulosic raw material. The device comprises: an acid liquid outputting unit, a raw material mixing unit, a feeding unit, a main ...
|
|
WO/2019/113032A1 |
High surface area metal catalysts, and methods of making and using the same, are described.
|
|
WO/2019/110800A1 |
Disclosed are spray-dried powders containing a mixture of structurally distinct human milk oligosaccharides, methods for the production of said spray-dried powder, its use for the manufacture of nutritional compositions, and nutritional ...
|
